# A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct07444437/  
OnCo record `nct07444437` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LM103 TILs Injection in non-small-cell lung cancer, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.

## Summary

A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07444437 by Suzhou BlueHorse Therapeutics Co., Ltd., with 45 participants planned, started 2026-02-26 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection and PD-1 / PD-L1 monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07444437
- Phase: 2
- Setting: A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations
- Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07444437: https://clinicaltrials.gov/study/NCT07444437

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07444437.json